8-K Announcements
6Material company update
Apr 2, 2026·SEC
Material company update
Mar 4, 2026·SEC
Material company update
Mar 2, 2026·SEC
Tyra Biosciences, Inc.(TYRA)Earnings, Financials & Key Ratios
TYRA•NASDAQ
$33.80
$1.82B mkt cap·Price updated May 6, 2026
AboutTyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.Show more
- Revenue$0
- EBITDA-$132M-27.6%
- Net Income-$120M-38.7%
- EPS (Diluted)-2.01-33.1%
- ROE-39.83%-26.1%
- ROIC-44.75%-17.5%
- Debt/Equity0.02+23.6%
TYRA Key Insights
Tyra Biosciences, Inc. (TYRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TYRA Price & Volume
Tyra Biosciences, Inc. (TYRA) stock price & volume — 10-year historical chart
Loading chart...
TYRA Growth Metrics
Tyra Biosciences, Inc. (TYRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-38.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-33.11%
Return on Capital
10 Years-57.86%
5 Years-30.39%
3 Years-38.16%
Last Year-43.28%
TYRA Recent Earnings
Tyra Biosciences, Inc. (TYRA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 2, 2026EPS
$0.57
Est $0.54
-5.6%
Revenue
—
Q4 2025
Nov 5, 2025EPS
$0.50
Est $0.50
+0.0%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.47
Est $0.53
+11.3%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.47
Est $0.49
+4.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.57vs $0.54-5.6% | — |
| Q4 2025 | Nov 5, 2025 | $0.50vs $0.50+0.0% | — |
| Q3 2025 | Aug 14, 2025 | $0.47vs $0.53+11.3% | — |
| Q2 2025 | May 8, 2025 | $0.47vs $0.49+4.1% | — |
Based on last 12 quarters of dataView full earnings history →
TYRA Peer Comparison
Tyra Biosciences, Inc. (TYRA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KROS | 438.47M | 11.78 | 5.12 | 67.75% | 35.65% | 14.25% | 0.06 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 MRUS | 6.83B | 90.00 | -26.87 | -12.38% | -6.54% | -50.62% | 0.02 | |
 ERAS | 3.09B | 10.90 | -15.80 | -36.7% | 0.12 | |||
 RGEN | 7.09B | 125.76 | 146.23 | 16.36% | 6.73% | 2.46% | 0.33 | |
 ICLR | 9.48B | 124.13 | 13.03 | 1.99% | 7.4% | 6.32% | 0.38 | |
 CRL | 8.97B | 181.73 | -62.45 | -0.85% | -3.59% | -4.34% | 0.95 |
Compare TYRA vs Peers
Tyra Biosciences, Inc. (TYRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TYRA Income Statement
Tyra Biosciences, Inc. (TYRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 8K | 47K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -8K▲ 0% | -47K▼ 487.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -487.5% | 100% | - | - | - | - |
| Operating Expenses | 3.12M | 9.25M | 26.29M | 58.93M | 79.94M | 104.18M | 132.76M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.33M | 2.09M | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 1.79M | 7.2M | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | -8K | -23K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.12M▲ 0% | -9.3M▼ 197.8% | -26.29M▼ 182.8% | -58.93M▼ 124.2% | -79.94M▼ 35.7% | -104.18M▼ 30.3% | -132.76M▼ 27.4% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -197.79% | -182.76% | -124.16% | -35.67% | -30.31% | -27.44% |
| EBITDA | -3.11M | -9.25M | -26.15M | -58.63M | -79.59M | -103.66M | -132.22M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -197.05% | -182.68% | -124.23% | -35.74% | -30.24% | -27.55% |
| D&A (Non-Cash Add-back) | 8K | 47K | 140K | 296K | 357K | 519K | 546K |
| EBIT | -3.12M | -9.34M | -26.29M | -58.93M | -79.94M | -104.18M | -119.95M |
| Net Interest Income | -999 | -999 | 13K | 3.65M | 10.81M | 17.7M | 0 |
| Interest Income | 0 | 0 | 13K | 3.65M | 10.81M | 17.7M | 0 |
| Interest Expense | 1K | 1K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -943K | -39K | -6K | 3.6M | 10.81M | 17.7M | 12.81M |
| Pretax Income | -4.07M▲ 0% | -9.34M▼ 129.7% | -26.29M▼ 181.6% | -55.33M▼ 110.4% | -69.13M▼ 25.0% | -86.48M▼ 25.1% | -119.95M▼ 38.7% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.06M▲ 0% | -9.31M▼ 129.5% | -26.29M▼ 182.3% | -55.33M▼ 110.4% | -69.13M▼ 25.0% | -86.48M▼ 25.1% | -119.95M▼ 38.7% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -129.52% | -182.31% | -110.41% | -24.96% | -25.09% | -38.7% |
| Net Income (Continuing) | -4.07M | -9.34M | -26.29M | -55.33M | -69.13M | -86.48M | -119.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10▲ 0% | -0.22▼ 130.6% | -0.63▼ 186.4% | -1.23▼ 95.2% | -1.62▼ 31.7% | -1.51▲ 6.8% | -2.01▼ 33.1% |
| EPS Growth % | - | -130.61% | -186.36% | -95.24% | -31.71% | 6.79% | -33.11% |
| EPS (Basic) | -0.10 | -0.22 | -0.63 | -1.23 | -1.62 | -1.51 | -2.01 |
| Diluted Shares Outstanding | 42.54M | 42.54M | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Basic Shares Outstanding | 42.54M | 42.54M | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
TYRA Balance Sheet
Tyra Biosciences, Inc. (TYRA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 127K | 15.28M | 304.06M | 257.29M | 211.67M | 347.46M | 265.45M |
| Cash & Short-Term Investments | 108K | 15.22M | 302.18M | 251.21M | 203.47M | 341.44M | 256M |
| Cash Only | 108K | 15.22M | 302.18M | 251.21M | 58.01M | 91.97M | 77.39M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 145.46M | 249.47M | 178.62M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 2M | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 6.08M | 8.2M | 4.02M | 9.45M |
| Total Non-Current Assets | 401K | 730K | 2.64M | 8.89M | 14.19M | 16.09M | 17.16M |
| Property, Plant & Equipment | 276K | 466K | 2.09M | 3.54M | 8.15M | 7.72M | 6.89M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 243K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 125K | 21K | 555K | 5.35M | 6.03M | 8.38M | 10.27M |
| Total Assets | 528K▲ 0% | 16.01M▲ 2932.4% | 306.7M▲ 1815.6% | 266.18M▼ 13.2% | 225.86M▼ 15.1% | 363.56M▲ 61.0% | 282.61M▼ 22.3% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 2932.39% | 1815.56% | -13.21% | -15.15% | 60.97% | -22.27% |
| Total Current Liabilities | 5.16M | 1.86M | 3.62M | 5.7M | 15.33M | 14.59M | 18.09M |
| Accounts Payable | 327K | 664K | 599K | 1.15M | 4.66M | 590K | 1.18M |
| Days Payables Outstanding | 14.92K | 5.16K | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 472K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.33M | 278K | 0 | 0 | 5.27M | 13.59M | 16.44M |
| Current Ratio | 0.02x | 8.22x | 84.09x | 45.13x | 13.80x | 23.81x | 14.67x |
| Quick Ratio | 0.02x | 8.22x | 84.09x | 45.13x | 13.80x | 23.81x | 14.67x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 114K | 27.79M | 1.35M | 2.65M | 6.26M | 5.81M | 5.34M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 5.34M |
| Capital Lease Obligations | 114K | 0 | 981K | 2.48M | 6.22M | 5.81M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 27.79M | 367K | 169K | 46K | 3K | 0 |
| Total Liabilities | 5.27M | 29.65M | 4.96M | 8.35M | 21.59M | 20.41M | 23.43M |
| Total Debt | 253K | 142K | 1.18M | 2.62M | 6.5M | 6.22M | 5.81M |
| Net Debt | 145K | -15.08M | -301M | -248.59M | -51.51M | -85.74M | -71.58M |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.03x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -3122.00x | -9297.00x | - | - | - | - | - |
| Total Equity | -4.74M▲ 0% | -13.64M▼ 187.7% | 301.74M▲ 2312.5% | 257.83M▼ 14.6% | 204.26M▼ 20.8% | 343.15M▲ 68.0% | 259.18M▼ 24.5% |
| Equity Growth % | - | -187.66% | 2312.47% | -14.55% | -20.78% | 68% | -24.47% |
| Book Value per Share | -0.11 | -0.32 | 7.28 | 6.16 | 4.78 | 6.00 | 4.35 |
| Total Shareholders' Equity | -4.74M | -13.64M | 301.74M | 257.83M | 204.26M | 343.15M | 259.18M |
| Common Stock | 0 | 0 | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | -4.74M | -14.08M | -40.37M | -95.7M | -164.83M | -251.31M | -371.26M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 381K | 770K | 393K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TYRA Cash Flow Statement
Tyra Biosciences, Inc. (TYRA) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.62M | -7.76M | -23.75M | -50.28M | -50.14M | -69.77M | -95.14M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -196.52% | -205.87% | -111.77% | 0.29% | -39.16% | -36.36% |
| Net Income | -4.07M | -9.34M | -26.29M | -55.33M | -69.13M | -86.48M | -119.95M |
| Depreciation & Amortization | 8K | 47K | 140K | 296K | 353K | 519K | 546K |
| Stock-Based Compensation | 0 | 439K | 2.89M | 10.59M | 0 | 22.8M | 28.01M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 934K | 17K | 3K | 3K | 12.28M | -5.88M | -3.75M |
| Working Capital Changes | 505K | 1.07M | -481K | -5.85M | 6.36M | -729K | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 461K | 1.02M | 1.49M | 0 | 0 | 0 | 3.37M |
| Cash from Investing | -20K | -312K | -645K | -559K | -144.6M | -98.4M | 72.46M |
| Capital Expenditures | -20K | -312K | -661K | -559K | -770K | -664K | -141K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 16K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 16 | 0 | 0 | 0 | 0 |
| Cash from Financing | 157K | 23.43M | 311.35M | 632K | 1.54M | 202.14M | 8.1M |
| Debt Issued (Net) | -8K | -17K | -9K | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 632K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -420K | 0 |
| Other Financing | 165K | 140K | 514K | 0 | 0 | 2.56M | 8.1M |
| Net Change in Cash | -2.48M▲ 0% | 15.36M▲ 719.1% | 286.96M▲ 1768.3% | -50.97M▼ 117.8% | -193.21M▼ 279.1% | 33.96M▲ 117.6% | -14.58M▼ 142.9% |
| Free Cash Flow | -2.64M▲ 0% | -8.07M▼ 206.1% | -24.41M▼ 202.2% | -50.84M▼ 108.3% | -50.91M▼ 0.1% | -70.44M▼ 38.4% | -95.28M▼ 35.3% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -206.1% | -202.24% | -108.33% | -0.13% | -38.36% | -35.27% |
| FCF per Share | -0.06 | -0.19 | -0.59 | -1.21 | -1.19 | -1.23 | -1.60 |
| FCF Conversion (FCF/Net Income) | 0.65x | 0.83x | 0.90x | 0.91x | 0.73x | 0.81x | 0.79x |
| Interest Paid | 1K | 1K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TYRA Key Ratios
Tyra Biosciences, Inc. (TYRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -18.25% | -19.77% | -29.92% | -31.6% | -39.83% |
| Return on Invested Capital (ROIC) | - | - | - | -886.03% | -74.03% | -38.1% | -44.75% |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.03x | 0.02x | 0.02x |
| Interest Coverage | -3122.00x | -9297.00x | - | - | - | - | - |
| FCF Conversion | 0.65x | 0.83x | 0.90x | 0.91x | 0.73x | 0.81x | 0.79x |
TYRA SEC Filings & Documents
Tyra Biosciences, Inc. (TYRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TYRA Frequently Asked Questions
Tyra Biosciences, Inc. (TYRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tyra Biosciences, Inc. (TYRA) grew revenue by 0.0% over the past year. Growth has been modest.
Tyra Biosciences, Inc. (TYRA) reported a net loss of $119.9M for fiscal year 2025.
Dividend & Returns
Tyra Biosciences, Inc. (TYRA) has a return on equity (ROE) of -39.8%. Negative ROE indicates the company is unprofitable.
Tyra Biosciences, Inc. (TYRA) had negative free cash flow of $95.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More TYRA
Tyra Biosciences, Inc. (TYRA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates